FGF21 confers neuroprotection in Parkinson's disease by activating the FGFR1-sirt1 pathway.

ABSTRACT:

Background

Parkinson's disease (PD) lacks disease-modifying therapies. Fibroblast growth factor 21 (FGF21) is implicated in PD, but its neuroprotective mechanisms via fibroblast growth factor receptor 1 (FGFR1)-sirtuin 1 (Sirt1) remain unclear.

Methods

Using 1-methyl-4-phenyl-1,2,3,6-te-trahydropyridine (MPTP)-induced PD mice and lipopolysaccharides (LPS)-stimulated BV2 microglia, this study employed recombinant adeno-associated virus (rAAV)-mediated FGF21 overexpression (OE). Multi-dimensional analyses (behavior, immunofluorescence, molecular docking, Western blot, PCR, transmission electron microscopy (TEM)) assessed FGF21's effects and mechanisms.

Results

FGF21^OE significantly improved motor deficits (gait, rotarod) and non-motor symptoms (depression/anx

SUBMITTER: Liu T 

PROVIDER: S-EPMC12570635 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature